Beta blocker therapy, decompensated heart failure, and inotropic interactions: Current perspectives

Israel Medical Association Journal

Volumn 14, Issue 3, 2012, Pages 184-189

  Zafrir, Barak ^a   Amir, Offer ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Beta blockers; Decompensated heart failure; Hospitalization; Inotropic therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CYCLIC AMP; DOBUTAMINE; ENOXIMONE; INOTROPIC AGENT; LEVOSIMENDAN; METOPROLOL SUCCINATE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN;

ARTERIAL PRESSURE; DRUG EFFICACY; DRUG MEGADOSE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEMODYNAMICS; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MORTALITY; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; CHRONIC DISEASE; DOBUTAMINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDRAZONES; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PYRIDAZINES;

EID: 84859096806     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-302.
2. CIBIS investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). A randomised trial. Lancet 1999; 353: 9-13.
3. Packer M, Coats AJ, Fowler MB, et al. Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119 (14): 1977-2016.
5. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997; 80: 207-9.
6. Dobre D, Van Veldhuisen DJ, DeJongste MJL, et al. Prescription of betablockers in patients with advanced heart failure and preserved ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007; 9: 280-6.
7. Massie BM, Nelson JJ, Lukas MA, et al.; the COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007; 99: 1263-8.
8. Flather MD, Shibata MC, Coats AJ, et al.; SENIORS investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25.
9. Paulus WJ. Novel strategies in diastolic heart failure. Heart 2010; 96: 1147-53.
10. Bristow MR, Shakar SF, Linseman JV, Lwes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001; 7 (2 Suppl 1): 8-12.
11. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESCIM). Eur Heart J 2008; 29 (19): 2388-442.
12. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffery DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33: 924-31.
13. O'Connor CM, Gattis WA, Zannad F, et al. Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. Eur J Heart Fail 1999; 1: 81-8.
14. Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker benefit according to severity of heart failure. Eur J Heart Fail 2003; 5: 281-9.
15. Gardner RS, Martin W, Carter R, McDonagh TA. Importance of beta blockade in the treatment of advanced heart failure. Heart 2003; 89: 1442-4.
16. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003; 289: 712-18.
17. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149 (2): 209-16.
18. Garty M, Shotan A, Gottlieb S, et al. The management, early and 1-year outcome in hospitalized patients with heart failure: a national heart failure survey in Israel - HFSIS. IMAJ Isr Med Assoc J 2007; 9: 227-33.
19. Braun E, Landsman K, Zuckerman R, Berger G, Meilik A, Azzam ZS. Adherence to guidelines improves the clinical outcome of patients with acutely decompensated heart failure. IMAJ Isr Med Assoc J 2009; 11: 348-53.
20. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; the IMPACT-HF investigators and coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol 2004; 43: 1534-41.
21. Gattis WA, O'Connor CM, Leimberger JD, Felker M, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003; 91: 169-74.
22. Butler J, Young JB, Abraham WT, et al. For the ESCAPE Investigators. Betablocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006; 47: 2462-9.
23. Metra M, Torp-Pedersen C, Cleland JGF, et al; the COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 2007; 9: 901-9.
24. Fonarrow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. Findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-9.
25. Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker continuation vs. interruption in patients with congestive heart failure hospitalized for decompensation episode. Eur Heart J 2009; 30: 2186-92.
26. Swedberg K. ß-Blockers in worsening heart failure: good or bad? Eur Heart J 2009; 30: 2177-9.
27. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the betablocker era. Clin Cardiol 2000; 23 (3 Suppl): 11-16.
28. Bollano E, Scharin TM, Hjalmarson A, Waagstein F, Andersson B. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart 2003; 89: 621-4.
29. Triposkiadis F, Dalampiras P, Kelepeshis G, Skoularigis J, Sitafidis G. Hemodynamic effects of dobutamine in patients with exacerbation of chronic systolic heart failure treated with low doses of carvedilol. Int J Clin Pharmacol Ther 2008; 46: 136-9.
30. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone vs. dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-9.
31. Metra M, Nodari S, D'Aloia S, et al. Beta blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoxamine before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248-8.
32. Jennings DL, Thompson ML. Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure. Ann Pharmacother 2009; 43 (11): 1872-6.
33. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31: 1336-40.
34. Follath F, Cleland JG, Just H, et al. Steering committee and investigators of the LIDO study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202.
35. Mebazza A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on ß-blockers in SURVIVE. Eur J Heart Fail 2009; 11: 304-11.
36. Bergh CH, Andersson B, Dahlstrom U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010; 12: 404-10.
37. Kirlidis TT, Skoularigis KT, Karayiannis G, Tsaknakis TK, Triposkiadis F. The influence of ß-blockade on the hemodynamic effects of levosimendan in elderly (≥70 years) patients with acutely decompensated systolic heart failure. Int J Clin Pharmacol Ther 2009; 47: 454-9.
38. Duygu H, Turk U, Ozdogan O, et al. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovasc Ther 2008; 26: 182-8.